Upper extremity deep vein thrombosis following BBIBP‐CorV COVID‐19 vaccine (Sinopharm vaccine): A case report

KEY CLINICAL MESSAGE: In patients with acute symptoms such as pain, swelling, and erythema of the upper extremities shortly after receiving COVID‐19 vaccines, even inactivated virus vaccines, these symptoms may indicate thrombosis, which may be due to the vaccination. ABSTRACT: BBIBP‐CorV COVID‐19 v...

Descripción completa

Detalles Bibliográficos
Autores principales: Riazi, Ali, Faghih Dinevari, Masood, Abbasian, Samaneh, Jabbaripour Sarmadian, Amirreza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264932/
https://www.ncbi.nlm.nih.gov/pubmed/37323251
http://dx.doi.org/10.1002/ccr3.7535
Descripción
Sumario:KEY CLINICAL MESSAGE: In patients with acute symptoms such as pain, swelling, and erythema of the upper extremities shortly after receiving COVID‐19 vaccines, even inactivated virus vaccines, these symptoms may indicate thrombosis, which may be due to the vaccination. ABSTRACT: BBIBP‐CorV COVID‐19 vaccine (Sinopharm vaccine) is an inactivated whole virus vaccine to control the COVID‐19 pandemic. Studies concluded that inactivated COVID‐19 vaccines do not increase the risk of thrombosis. This report presents a 23‐year‐old man with the chief complaint of severe pain, swelling, and erythema of the right upper extremity following his second dose of the Sinopharm vaccine. Duplex ultrasound of the right upper extremity revealed upper extremity deep vein thrombosis, and treatment started with oral anticoagulation. It is probably the first upper extremity deep vein thrombosis case following inactivated COVID‐19 vaccines.

Ejemplares similares